TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06652425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate temperature (22°C) group
Description: The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
Study: NCT06652776

Intervention type: OTHER
Intervention: Pharmacological treatment
Description: Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation

Intervention type: OTHER
Intervention: Pharmacological treatment
Description: All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation
Study: NCT06466395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: Given by IV
Study: NCT06573892

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
Study: NCT06653712

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood
Study: NCT06650397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified maize
Description: Maize that has been grown to have higher amounts of iron and zinc.
Study: NCT06381921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBS-PPSM intervention
Description: IBS-PPSM intervention includes 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting.
Study: NCT04730271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Subjects will be implanted with an ATTUNE Primary total knee replacement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: Subjects will be implanted with an ATTUNE Primary total knee replacement.
Study: NCT05449756

Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
Study: NCT06650397

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Traditional maize
Study: NCT05782140

Intervention type: DEVICE
Intervention: Mayo Clinic Watch Device
Description: Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
Study: NCT04481399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention for Early Childhood Development
Description: The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Community Health Worker Routine
Description: Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
Study: NCT04929834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrating emollient + body lotion for immunotherapy-related side effects
Description: Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
Study: NCT05922540

Intervention type: OTHER
Intervention: Intravenous thrombolysis
Description: Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients

Intervention type: OTHER
Intervention: Intravenous thrombolysis
Description: Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
Study: NCT05196230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition (Social Story)
Description: The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Condition (360° Video)
Description: The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
Study: NCT05190562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet
Description: Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
Study: NCT04682977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)
Description: IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual primary care services
Description: Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
Study: NCT06290609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset
Description: The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
Study: NCT04356196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT06061601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton stroke group
Description: The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
Study: NCT05935826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential Amino Acid Supplement by Amino Co
Description: 2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
Study: NCT06570096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% then bupivacaine 0.5%
Description: Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% and bupivacaine 0.5%
Description: Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
Study: NCT05632952

Intervention type: DEVICE
Intervention: Intraperitoneal Onlay Mesh positioning Plus
Description: Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision.
Study: NCT05991141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apnea
Description: In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
Study: NCT05508633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alverine Citrate
Description: Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alverine Citrate
Description: Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
Study: NCT05600218

Intervention type: DRUG
Intervention: No intervention - Observational study
Description: Real life drug evaluation
Study: NCT04239534

Intervention type: DEVICE
Group type: OTHER
Intervention: Convergence Of Epicardial And Endocardial RF Ablation
Description: The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
Study: NCT06161363

Intervention type: OTHER
Intervention: The Morisky Medication Adherence Scale
Description: The Morisky Medication Adherence Scale will be completed bu the patients
Study: NCT06331052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided Focused Ultrasound Ablation
Description: 3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
Study: NCT05340686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Physical Exercise
Description: Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing Physical Exercise
Description: Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information about physical exercise
Description: Written and oral information about physical exercise recommendations, on one occasion, by researcher
Study: NCT05811104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential bilateral theta burst stimulation
Description: Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sequential bilateral theta burst stimulation
Description: Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
Study: NCT05458479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
Study: NCT05663398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Description: Oral, a nonsteroidal anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
Description: Oral, a nonsteroidal anti-inflammatory drug
Study: NCT05394337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by vein (IV)
Study: NCT05102994

Intervention type: DIAGNOSTIC_TEST
Intervention: mutation test
Description: detect the tumor-related mutation in introcular fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: mutation test
Description: detect the tumor-related mutation in introcular fluid
Study: NCT05507671

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Bacillus Calmette-Guérin) vaccine
Description: Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
Study: NCT05236790

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye
Description: Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
Study: NCT05383170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [KEYTRUDA®]
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [KEYTRUDA®]
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [KEYTRUDA®]
Description: IV infusion
Study: NCT04979728

Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples

Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples

Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples

Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples

Intervention type: OTHER
Intervention: At Home Self-Collections
Description: Directly observed at home self-collection of blood samples
Study: NCT05701800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1468
Description: Sterile liquid dispersion for injection
Study: NCT05507671

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion